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2366The low-density lipoprotein re-
ceptor (LDLR) is the major and
preferential pathway through
which LDL is cleared from the
circulation, predominantly by the
liver. LDL particles that bind to
the LDLR are internalized into
clathrin-coated pits and subse-
quently undergo lysosomal deg-
radation. The LDLR is then
recycled back to the plasma mem-
brane (1). Familial hypercho-
lesterolemia (FH) is a common
autosomal codominant disorder
(prevalence 1 in 500), character-
ized by elevated LDL-cholesterol
(LDL-C) levels, premature coro-
nary heart disease, and tendon
xanthomata. Approximately 90%
ofFHis causedbymutations in the
LDLR gene (2).
As an inhibitor of the LDLR,
proprotein convertase subtilisin/
kexin type 9 (PCSK9) has emerged as a new and important
regulator of circulating LDL-C levels (3). Paradoxically,
statins, the most efﬁcient LDL-C–lowering agents currentlypage 2374available, simultaneously up-regulate the expression of PCSK9
and that of LDLR (4–6). PCSK9 is secreted primarily from
liver cells (7). It binds to and is subsequently internalized with
the LDLR, thereby promoting degradation of the receptor in
the lysosome rather than recycling to the plasma membrane
(8,9). This explains the positive correlation (r ¼ 0.24 to 0.58)
between circulating PCSK9 and LDL-C levels in the pop-
ulation (3). Infusion of monoclonal antibodies (mAbs) tar-
geting PCSK9 in phase I and phase II clinical trials reduced
circulating LDL-C levels both in monotherapy and in com-
bination with statins, down to levels only seen in monogenic
hypolipidemias (10,11). These treatments also lowered LDL-
C below target levels in the vast majority of patients with
severe hypercholesterolemias, such as those with heterozygous
familial hypercholesterolemia (HeFH) (12,13).
It is not known if elevated PCSK9 levels constitute a
greater risk for patients with HeFH who already have
reduced LDLR levels compared with patients with nonfa-
milial hypercholesterolemia (non-FH). Because statin
treatment appears to reduce LDL-C levels variably in some
patients with HeFH as a function of their LDLR molecular
defects (14), it is also important to determine if patients with
HeFH with distinct LDLR defects would be differently
sensitive to elevated plasma PCSK9 levels (and hence
indirectly to PCSK9 inhibition). To that end, we analyzed
relationships between plasma lipid and PCSK9 levels in 392
patients with HeFH carrying either a class 2 (D206E orD154N) or class 5 (V408M) LDLR missense mutation as
well as in 152 controls with non-FH. We also determined
the effects of recombinant PCSK9 on the cell surface
expression of the LDLR in primary ﬁbroblasts and lym-
phocytes isolated from those individuals.
Methods
Patients with FH. Fasting plasma samples were collected
from patients with untreated hypercholesterolemia referred
to the Groote Schuur Hospital lipid clinic in Cape Town,
South Africa (15). Genomic DNA was extracted from blood,
and plasma was archived at 80C. Patients with dysbeta-
lipoproteinemia (16), familial defective apolipoprotein B-100
(apoB-100) (15), or PCSK9 gain-of-function mutations (17)
were excluded. The FH phenotype, deﬁned as total
cholesterol (TC) >7.5 mmol/l attributable to an increase in
LDL-C, together with tendon xanthomata in the patient or
ﬁrst-degree relative (deﬁnite FH) or with a family history of
hypercholesterolemia and premature ischemic heart disease
(probable FH), was identiﬁed in 1,029 patients. DNA sam-
ples were screened for founder LDLR mutations in South
Africa (18). FH was conﬁrmed genetically in 473 patients,
with 3 founder LDLR missense mutations accounting for
83% of the FH cases (237 LDLR-D206E, 117 LDLR-
V408M, and 38 LDLR-D154N heterozygous carriers).
Patients with familial hypobetalipoproteinemia and
normolipidemic individuals. Plasma samples were obtained
from 48 patients with genetically conﬁrmed heterozygous
familial hypobetalipoproteinemia (FHBL) from the Royal
Perth Hospital, Perth, Australia. Among these patients,
24 had apoB missense mutations (R463W or L343V) and
24 had truncating apoB defects (19,20). Control plasma
samples (n ¼ 152) were obtained from normolipidemic in-
dividuals, including 26 nonaffected FHBL family members
and 126 healthy volunteers.
Plasma lipid and PCSK9 measurements. Plasma TC,
triglyceride, high-density lipoprotein cholesterol (HDL-C),
apoA-I, and apoB levels were measured in accredited labo-
ratories before any lipid-lowering medications were started.
LDL-C concentrations were calculated using the Friede-
wald formula. PCSK9 concentrations were measured in
duplicate by enzyme-linked immunosorbent assay using a
commercial kit (Cyclex, Nagano, Japan) previously validated
in our laboratory (21).
Primary lymphocytes and ﬁbroblasts. Ethics approval was
obtained from the University of Cape Town, Cape Town,
South Africa.Written informed consent was obtained from all
patients. Primary lymphocytes were isolated and puriﬁed from
20 ml of venous blood obtained after an overnight fast from
19 statin-treated patients with HeFH (7 LDLR-D206E,
7 LDLR-V408M, and 5 LDLR-D154N) (Online Table), as
well as from 12 healthy normolipidemic controls, using
Lymphoprep (Axis Shield,Oslo, Norway). Lymphocytes were
plated in 6-well plates (106 cells/well) in RPMI containing
10% lipoprotein-deﬁcient serum (LPDS) þ mevastatin
(10 mg/ml) for 24 h. Twelve microliters of phosphate-buffered
Figure 1
Effect of Increasing Concentrations of rPCSK9-D374Y on LDLR Cell Surface Expression in Primary Skin Fibroblasts From
Control Individuals (WT) and Patients With FH Carrying the D206E, V408M, or D154N LDLR Missense Mutations
Fibroblasts were grown in 0.5% fetal calf serum with mevastatin 10 mg/ml for 24 h. Recombinant proprotein convertase subtilisin/kexin type 9 (PCSK9) was added to the culture
medium 4 h prior to ﬂow cytometric analysis of cell surface low-density lipoprotein receptor (LDLR) expression. Histograms represent the mean  SEM of 3 independent
experiments. *p < 0.01 versus 0 ng/ml experimental condition. Representative ﬂuorescence charts are presented for each genotype. FH ¼ familial hypercholesterolemia;
LDL ¼ low-density lipoprotein; WT ¼ wild type.
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2367saline (PBS) solution containing 0.1 mg/ml recombinant
PCSK9-D374Y (Cyclex) was added to a subset of wells
(PCSK9 ﬁnal concentration 600 ng/ml) for an additional 4 h.
Primary ﬁbroblasts isolated from forearm skin biopsies of
4 patients carrying 1 of the followingLDLRmolecular defects
were grown in Dulbecco modiﬁed Eagle medium (DMEM)
containing 20% fetal calf serum (FCS): LDLR-D206E,
LDLR-V408M, LDLR-D154N, or only wild-type (WT)
LDLR. Fibroblasts were plated in 96-well plates (104 cells/
well) in DMEM containing 0.5% FCS for 24 h and subse-
quently supplemented with mevastatin 10 mg/ml for 24 h.
Increasing doses (0, 150, 300, and 600 ng/ml) of rPCSK9-
D374Y (Cyclex) were added to the medium for 4 h.
Throughout our experiments, we used rPCSK9-D374Y, a
variant that displays 10 times increased afﬁnity for the
LDLR compared with WT PCSK9 (22). We ascertained in
control ﬁbroblasts that 1,500, 3,000, and 6,000 ng/ml WT
rPCSK9 (Cyclex) are as potent as 150, 300, and 600 ng/m
rPCSK9-D374Y, respectively, at decreasing LDLR cell
surface expression (Online Fig. 1A).
Flow cytometry. The culture medium was removed. The
cells were washed gently with 150 ml of PBS and then lifted
with 50 ml of Accutase (Stemgent, Cambridge, Massachu-
setts). For each experimental condition, 104 cells were
resuspended, washed twice in 150 ml of ice-cold PBS con-
taining 1% bovine serum albumin (BSA) and 0.1% NaN3
(Sigma-Aldrich, Saint-Quentin Fallavier, France), and
incubated with phycoerythrin-conjugated mAbs against the
LDLR or an immunoglobulin G1 isotype control (R&DSystems, Lille, France) at 0.625 mg/ml for 30 min at 4C in
the dark. Cells were then washed twice in ice-cold PBS
containing 1% BSA and 0.1% NaN3 before ﬁxation with
100 ml of PBS containing 1% paraformaldehyde. Acquisition
was performed using a ﬂuorescence-activated cell sorting array
cytometer equipped with a plate reader (Becton Dickinson,
Le Pont deClaix, France). Forward-scatter versus side-scatter
gates were set to include only viable cells. A minimum of
2,500 cells were analyzed for LDLR expression using the
Cytobank software (Mountain View, California).
Statistical analysis. Normally distributed continuous vari-
ables are shown as mean  SD and were compared using
Student t tests. Continuous variables not normally distributed
are depicted as median (interquartile range [IQR]) and were
compared using Wilcoxon rank-sum tests. A chi-square test
was used to compare categorical variables. Spearman correlation
coefﬁcients (r) were calculated to assess the relationship be-
tween parameters (23). For each group of patients, the associ-
ation between levels of PCSK9 and plasma lipids was assessed
using linear regression analysis. Products of the centered
covariables were compared between patient groups to test
potential differences in the strengths of associations. No cor-
rections for multiple comparisons were applied. Throughout,
p values <0.05 were considered statistically signiﬁcant.
Results
To evaluate whether PCSK9 differentially modulates the
expression of the LDLR in FH, we used 4 lines of primary
Figure 2 Effect of PCSK9 on LDLR Cell Surface Expression in Primary Lymphocytes From Control Individuals (WT) and Patients With FH
Lymphocytes from 7 LDLR-D206E, 7 LDLR-V408M, 5 LDLR-D154N, and 12 healthy normolipidemic controls were grown in lipoprotein-deﬁcient serum (LPDS) with mevastatin for
24 h. Recombinant PCSK9 was added to the culture medium 4 h prior to ﬂow cytometric analysis of cell surface LDLR expression. Histograms represent the mean  SEM of 5 to
12 experiments performed in duplicate. *p < 0.025 versus LPDS þmevastatin experimental condition. One representative ﬂuorescence chart is represented above each group.
Abbreviations as in Figure 1.
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2368skin ﬁbroblasts. Three were isolated from patients with FH,
each of whom carried 1 of the 3 most prevalent South Af-
rican LDLR mutations (i.e., D206E, V408M, or D154N),
and 1 from a control individual. After 24 h of mevastatin
treatment in serum-depleted culture conditions to maximally
induce the expression of LDLR, increasing concentrations
of rPCSK9-D374Y were added to the ﬁbroblasts. The
LDLR abundance at the plasma membrane was subse-
quently assessed by ﬂow cytometry (Fig. 1). As anticipated,
baseline LDLR expression was signiﬁcantly lower in FH-
D206E, FH-V408M, and FH-D154N ﬁbroblasts than in
control ﬁbroblasts, with median ﬂuorescence intensity
(MFI) levels of 453  35, 448  19, and 498  32 versus
625  15, respectively (p < 0.01 vs. controls). The addition
of 150, 300, and 600 ng/ml rPCSK9-D374Y for 4 h to the
cells decreased LDLR levels in a dose-dependent manner
by up to 82  7% in FH cells (75  11% in FH-D206E,
81  9% in FH-V408M, and 89  10% in FH-D154N)
and by up to 77  8% in control cells (p > 0.2 vs. controls).
To establish that the results obtained with rPCSK9-D374Y
can be extrapolated to WT PCSK9, we showed in each
ﬁbroblast line that 6,000 ng/ml wild-type rPCSK9 was aspotent at decreasing LDLR levels as 600 ng/ml rPCSK9-
D374Y (Online Fig. 1B).
Because the LDLR measured at the surface of primary
cells isolated from patients with HeFH is the product of
both WT and mutant LDLR alleles, we determined if
LDLR-WT, LDLR-D206E, LDLR-V408M, and LDLR-
D154N were individually similarly sensitive to PCSK9.
Compared with LDLR-WT, baseline cell surface expression
of the D206E and D154N mutants was reduced by 40% and
that of the V408M mutant by 90% (Online Fig. 2A). In the
presence of PCSK9, the expression of LDLR-WT, LDLR-
D206E, and LDLR-D154N were reduced to similar extents
(by 45%), indicating that both LDLR-D206E and LDLR-
D154N are as sensitive to PCSK9-mediated degradation as
LDLR-WT, in agreement with their class 2 LDLR defect
status (slow processing) (1). In contrast, the cell surface
expression of V408M-LDLR was not signiﬁcantly affected
by PCSK9, in agreement with its class 5 defect status
(recycling defect) (1). We ascertained by Western blot that
transfections of the various constructs resulted in detectable
expression of the LDLR protein (both the 120-kDa pre-
cursor and 160-kDa mature forms) (Online Fig. 2B). For
Table 1 Clinical Characteristics of Controls, Patients With FH, and Patients With FHBL
Controls
(n ¼ 152)
FH-D206E
(n ¼ 237)
FH-V408M
(n ¼ 117)
FH-D154N
(n ¼ 38)
FHBL
(n ¼ 48)
Age, yrs 32  18 39  15 36  16 39  16 37  17
Sex, M/F 43/57 52/48 42/58 50/50 69/31
CVD 0 24* 33* 23* 0
DM 3 1 0 8 4
DBP, mm Hg d 130  22 133  21 129  19 d
SBP, mm Hg d 81  12 80  12 79  11 d
TC, mmol/l 4.66  0.96 8.64  1.85* 9.30  1.99y 8.75  2.29* 2.47  0.61*
TG, mmol/l 1.23 (0.38–2.1) 1.50 (0.48–2.52) 1.37 (0.58–2.15) 1.48 (0.33–2.63) 0.59 (0.19–0.9)*
HDL-C, mmol/l 1.28  0.27 1.24  0.40 1.20  0.32 1.24  0.33 1.31  0.41
Non-HDL-C, mmol/l 3.39  0.95 7.40  1.86* 8.11  2.01y 7.50  2.35* 1.16  0.62*
LDL-C, mmol/l 2.87  0.86 6.74  1.78* 7.50  1.87y 6.83  2.07* 0.89  0.36*
apoB, g/l 0.92  0.26 1.59  0.41* 1.72  0.48* 1.57  0.48* 0.29  0.10*
apoA-I, g/l 1.41  0.19 1.18  0.30 1.15  0.32 1.14  0.27 1.35  0.30
PCSK9, ng/ml 180 (65–357) 368 (111–497)* 411 (120–532)* 389 (95–511)* 133 (25–240)*
Values are mean  SD, %, or mean (interquartile range) unless otherwise indicated. *p < 0.01 versus controls. yp < 0.05 versus both controls and FH-D206E.
apo ¼ apolipoprotein; CVD ¼ cardiovascular disease; DBP ¼ diastolic blood pressure; DM ¼ diabetes mellitus; FH ¼ familial hypercholesterolemia; FHBL ¼ familial hypobetalipoproteinemia; HDL-C ¼ high-
density lipoprotein cholesterol; LDL-C ¼ low-density lipoprotein cholesterol; PCSK9 ¼ proprotein convertase subtilisin/kexin type 9; SBP ¼ systolic blood pressure; TC ¼ total cholesterol; TG ¼ triglycerides.
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2369each LDLR variant, expression of the 160-kDa mature form
paralleled the cell surface expression of the receptor assessed
by ﬂow cytometry with or without PCSK9. Noteworthy, the
160-kDa mature form of LDLR-V408M was virtually ab-
sent and did not appear to be sensitive to PCSK9, whereas
expression of the LDLR-V408M 120-kDa precursor was
similar to that of LDLR-WT and was sensitive to PCSK9-
mediated inhibition intracellularly (Online Fig. 2B).
We further assessed the effects of PCSK9 on the cell
surface expression of LDLR using freshly isolated lympho-
cytes from 12 normolipidemic individuals as well as from 7
LDLR-D206E, 7 LDLR-V408M, and 5 LDLR-D154N
patients with HeFH (Online Table). After 24 h of mevas-
tatin treatment in LPDS culture conditions to induce
expression of the LDLR, 600 ng/ml rPCSK9-D374Y was
added to the lymphocytes for 4 h and the LDLR abundance
at their surface assessed by ﬂow cytometry (Fig. 2). Baseline
LDLR expression was signiﬁcantly lower in FH-D206E,
FH-V408M, and FH-D154N than in WT lymphocytes,
with MFI levels of 325  31, 221  29, and 342  32
versus 459  52, respectively (p < 0.05 vs. WT). Of note,
LDLR expression was signiﬁcantly lower in FH-V408M
lymphocytes than in FH-D206E and FH-D154N lympho-
cytes (p< 0.05). The addition of 600 ng/ml rPCSK9-D374Y
to the culture media signiﬁcantly decreased LDLR MFI
levels down to 190  16 in FH-D206E, 125  24 in FH-
V408M, 166  35 in FH-D154N, and 281  31 in WT
lymphocytes. The magnitudes of these decreases were similar
at 45  10% in HeFH (42  9% in FH-D206E, 43  12%
in FH-V408M, and 51  9% in FH-D154N) and at 39 
8% in non-FH controls, respectively (p > 0.1 vs. WT).
To evaluate the sensitivity of patients with HeFH to
elevated circulating PCSK9 levels in relationship to the
LDLR defect, we measured plasma PCSK9 in 392 patients
with nontreated HeFH carrying a class 2 D206E (n ¼ 237),
class 2 D154N (n ¼ 38), or class 5 V408M (n ¼ 117)LDLR missense mutation. It is important to note that none
of these patients were taking statins, thus eliminating the
potential artifact relating to the ability of these drugs to
coinduce PCSK9 and LDLR expression. We also included
in this analysis 2 control groups: 152 normolipidemic con-
trol individuals and 48 patients with heterozygous FHBL
(Table 1). There was no signiﬁcant difference between the
control group and the various groups of patients with FH or
FHBL in terms of age and circulating HDL-C and apoA-I
levels. Compared with controls, heterozygous carriers of the
D206E, D154N, or V408M LDLR missense mutations
presented with increased plasmaTC, non–HDL-C, LDL-C,
and apoB concentrations, associated with a higher incidence
of cardiovascular disease. Of the 3 groups of patients with
HeFH studied, carriers of the class 5 LDLR-V408M mu-
tation were the most severely hypercholesterolemic, as pre-
viously reported (24). In contrast, patients with FHBL had
lower circulating TC, non–HDL-C, LDL-C, apoB, and
triglyceride levels than controls (Table 1). Plasma PCSK9
levels were markedly increased in FH-D206E (368 ng/ml
[IQR: 111 to 497 ng/ml]), FH-V408M (411 ng/ml [IQR:
120 to 532 ng/ml]), and FH-D154N (389 ng/ml [IQR: 95
to 511 ng/ml]) but reduced in FHBL (133 ng/ml [IQR: 25
to 240 ng/ml]), compared with controls (180 ng/ml [IQR: 65
to 357 ng/ml]), consistent with a dominant role for the
LDLR in PCSK9 removal (25).
We found a positive and signiﬁcant (Fig. 3) correlation
between circulating PCSK9 and non–HDL-C levels in
normolipidemic controls (Spearman correlation coefﬁcient
r ¼ 0.29; p ¼ 0.01), FH-D206E (r ¼ 0.27; p ¼ 0.02), FH-
V408M (r ¼ 0.34; p ¼ 0.01), and FH-D154N (r ¼ 0.35;
p ¼ 0.04) but not in the FHBL group (r ¼ 0.19; p ¼ 0.15).
Similar results were obtained when LDL-C or apoB were
plotted against PCSK9 in the control and the 3 FH groups
(not shown), as also indicated by linear regression analyses
(Table 2). Circulating PCSK9 levels were signiﬁcantly and
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2370positively associated with TC, LDL-C, and non–HDL-C
levels in the controls, FH-D206E, FH-V408M, and
FH-D154N groups. PCSK9 levels were also signiﬁcantly
associated with apoB levels in controls, FH-D206E, and
FH-V408M, with a similar trend (p ¼ 0.065) for the
smallest FH group (D154N). The strengths of these asso-
ciations did not differ signiﬁcantly between the 3 FH groups
and the controls (p for interaction >0.4 for all). There was
no signiﬁcant association between plasma lipid or apolipo-
protein levels and PCSK9 concentrations in patients with
FHBL. We did not observe any signiﬁcant correlation be-
tween plasma HDL-C or apoA-I levels and PCSK9 levels in
any of the groups studied (Table 2).
Discussion
This study investigated whether elevated PCSK9 levels may
constitute a greater risk for patients with naturally reduced
LDLR function, such as those with HeFH. We ﬁrstFigure 3
Correlations Between Plasma PCSK9 and Non–HDL-Choles
FHBL, 237 Patients With FH Who Are Heterozygous Carrier
Heterozygous Carriers of the V408M LDLR Mutation, and 3
LDLR Mutation
Spearman correlation coefﬁcients (R) and statistical signiﬁcance are indicated. HDL ¼ himeasured the PCSK9-mediated inhibition of the LDLR at
the cell surface of primary ﬁbroblasts and lymphocytes iso-
lated from patients with HeFH carrying either a class 2
(D206E or D154N) or class 5 (V408M) LDLR missense
mutation and from non-FH controls. We showed that
PCSK9 inhibits the expression of the LDLR to similar
extents at the surface of those cells, irrespective of their
speciﬁc LDLR mutation. Furthermore, the positive corre-
lations that exist in normolipidemic individuals between
circulating PCSK9 and TC, non–HDL-C, LDL-C, or
apoB levels were also evident among patients with HeFH
carrying a D206E, V408M, or D154N LDLR defect. The
strengths of these associations were similar in controls and in
the 3 groups of patients with FH.
In vitro, we found that recombinant PCSK9 reduced cell
surface LDLR expression in a dose-dependent manner by
77% in control and 82% in FH ﬁbroblasts. Likewise,
rPCSK9 reduced LDLR abundance by 39% at the plasma
membrane of non-FH lymphocytes and 45% in HeFHterol Levels in 152 Normolipidemic Individuals, 48 Patients With
s of the D206E LDLR Mutation, 117 Patients With FH Who Are
8 Patients With FH Who Are Heterozygous Carriers of the D154N
gh-density lipoprotein; ns ¼ not signiﬁcant; other abbreviations as in Figure 1.
Table 2 Associations Between Plasma Lipid and PCSK9 Levels in Controls, Patients With FH, and Patients With FHBL
Controls
(n ¼ 152)
FH-D206E
(n ¼ 237)
FH-V408M
(n ¼ 117)
FH-D154N
(n ¼ 38)
FHBL
(n ¼ 48)
TC, mmol/l Beta
(95% CI)
p value
0.25
(0.11 to 0.39)
0.0003
0.22
(0.10 to 0.32)
0.0005
0.27
(0.13 to 0.43)
0.0003
0.28
(0.02 to 0.55)
0.043
0.03
(0.09 to 0.17)
0.7
HDL-C, mmol/l Beta
(95% CI)
p value
0.01
(0.15 to 0.17)
0.77
0.02
(0.19 to 0.18)
0.70
0.03
(0.25 to 0.19)
0.86
0.02
(0.24 to 0.29)
0.80
0.00
(0.17 to 0.18)
0.92
LDL-C, mmol/l Beta
(95% CI)
p value
0.22
(0.09 to 0.35)
0.0003
0.20
(0.08 to 0.33)
0.0002
0.24
(0.10 to 0.39)
0.0002
0.25
(0.01 to 0.54)
0.048
d
Non–HDL-C, mmol/l Beta
(95% CI)
p value
0.26
(0.12 to 0.40)
0.0003
0.23
(0.11 to 0.35)
0.0002
0.28
(0.14 to 0.43)
0.0002
0.28
(0.02 to 0.56)
0.042
0.04
(0.10 to 0.18)
0.6
apoB, g/l Beta
(95% CI)
p value
0.070
(0.031 to 0.112)
0.001
0.064
(0.021 to 0.108)
0.002
0.081
(0.037 to 0.119)
0.005
0.057
(0.001 to 0.120)
0.065
0.009
(0.021 to 0.003)
0.29
apoA-I, g/l Beta
(95% CI)
p value
0.010
(0.015 to 0.026)
0.19
0.015
(0.019 to 0.034)
0.21
0.017
(0.044 to 0.002)
0.20
0.029
(0.013 to 0.073)
0.27
0.002
(0.017 to 0.016)
0.51
Beta is the linear regression unstandardized coefﬁcient indicating the change in plasma lipid levels (in mmol/l) and apolipoprotein levels (in g/l) per 100-ng/ml increase in PCSK9.
Abbreviations as in Table 1.
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2371lymphocytes. There was no difference when the results were
analyzed separately for FH ﬁbroblasts and lymphocytes by
genotype. Tested individually, LDLR-WT, LDLR-D206E,
and LDLR-D154N were found to have similar sensitivity
to PCSK9-mediated degradation, whereas expression of
LDLR-V408M at the cell surface was extremely low and not
sensitive to PCSK9. Because we focused on class 2 and class 5
LDLR defects, which are respectively associated with slow
processing and an inability to recycle after endocytosis (1), the
receptors expressed at the surface of FH ﬁbroblasts and
lymphocytes were primarily, if not almost exclusively (for FH-
V408M), the product of the WT LDLR allele. It is therefore
unlikely that a reduced or absent response to PCSK9 of the
mutant LDLR combined with an enhanced response of the
LDLR-WT would account for the overall similar effects of
PCSK9 that we observed in ﬁbroblasts and lymphocytes
from patients with HeFH compared with WT. Taken
together, our results thus indicated that a given concentration
of PCSK9 similarly reduced the relative (but not absolute)
abundance of the LDLR at the cell surface. In other words,
cells from patients with class 2 and class 5 HeFH were as
sensitive as cells from patients with non-FH to PCSK9-
mediated LDLR degradation. One inherent limitation to
this approach is the use of peripheral primary cell types to
decipher how PCSK9 actually acts at the surface of hepato-
cytes, by far the most relevant cellular model to investigate
LDL metabolism. For instance, the adaptor protein defective
in autosomal dominant hypercholesterolemia that allows
LDLR endocytosis in hepatocytes is not required in primary
ﬁbroblasts (26). Given that the sensitivity of LDLR to
PCSK9-mediated degradation is comparable in HeFH
and control ﬁbroblasts, as well as in HeFH and control lym-
phocytes, we may reasonably assume that PCSK9 similarly
inhibits LDLR in HeFH and non-FH hepatocytes.Study limitations. Consistent with previous reports (3), we
found positive correlations between plasma PCSK9 and
TC, non–HDL-C, LDL-C, and apoB levels in non-FH
controls. We also found positive correlations of the same
magnitude among patients with HeFH with a D206E,
V408M, or D154N missense LDLR defect, a result that
could only be obtained in untreated patients (27). In line
with these results, we previously reported that low LDL-C
levels in untreated individuals with genetic HeFH from
the Netherlands were primarily observed either in patients
who carry LDLR mutations generally associated with a mild
phenotype or in patients who have very low circulating
PCSK9 levels (21). In the present study, we screened the
LDLR only for mutations in patients that fulﬁlled stringent
criteria for the clinical diagnosis of HeFH. We may there-
fore have failed to identify a few individuals with LDLR
mutations but a less severe phenotype because LDL-C levels
reﬂect a multitude of genetic and environmental inﬂuences.
From our clinical experience of cascade screening in families
with known LDLR mutations, only very few adults would
have been excluded incorrectly, and this is unlikely to have
affected our results (1,24,28). To date, more than 250 pa-
tients with HeFH of various genotypes with LDL-C >2.6
mmol/l while on statins have been enrolled in phase II trials
of mAbs targeting PCSK9 (10–13). Both REGN727/
SAR236553 and AMG145 safely lowered LDL-C levels
in those patients by up to 60% at their maximal doses, with
only a handful of patients not reaching the endpoint.
Although unlikely, it cannot be ruled out entirely that a
few LDLR mutations might impact the cellular response to
PCSK9 and thus PCSK9 inhibition in some rare HeFH
cases. Likewise, it cannot be excluded that patients with
HeFH with constitutively very high baseline PCSK9 levels
might not respond as well and/or for as long to the
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2372lowering of LDL-C levels by PCSK9 inhibitors infused once
or twice a month at standard doses (e.g., 140 to 150 mg).
Of note, an absence of correlation between PCSK9 and
plasma TC or non–HDL-C levels was observed among
patients with FHBL, indicating that variations in PCSK9
levels do not modulate circulating LDL levels signiﬁcantly
in this lipid disorder. In fact, the naturally low LDL levels in
FHBL result primarily from a reduced production of apoB-
100 containing very low-density lipoprotein precursors
rather than from an increased catabolism of LDL particles
by the LDLR (19,20). Thus, reduced LDL production is
the determining factor in FHBL, and PCSK9 does not
appear to signiﬁcantly modulate this pathway.
Conclusions
In the present study, we demonstrated that elevated
PCSK9 levels were equally detrimental for patients with
HeFH and those with non-FHdan increase in circulating
PCSK9 of 100 ng/ml led, on average, to an increase in
plasma LDL-C of 0.20 to 0.25 mmol/l in patients with
non-FH and those with HeFH. This explains at least in
part why patients with non-FH and those with HeFH
respond equally well to circulating PCSK9 inhibitors
(10,11). Because patients with HeFH only have 1 fully
functional LDLR allele, their baseline PCSK9 and LDL-C
levels are usually very high, and only a minority of them
reach their optimal LDL-C levels on statins (29,30). Thus,
none of our 19 HeFH lymphocyte donors achieved LDL-C
target levels of <3 mmol/l despite high-dose statin treat-
ment with or without ezetimibe. Therefore, even if patients
with non-FH and those with HeFH respond equally well
to PCSK9 inhibitors in relative terms, mAbs targeting
PCSK9 in combination with statins will in absolute terms
reduce LDL-C levels more in HeFH than in non-FH. It
remains to be seen whether these new treatments will
translate into improved cardiovascular outcomes for patients
with HeFH.
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